US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Intellipharmaceutics International Inc. - Common Stock (TSX:IPCI)

N/A UNCHANGED
Last Price Updated: 10:01 AM EST, Mar 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellipharmaceutics International Inc. - Common Stock

News headline image
Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
Via ACCESSWIRE
News headline image
Intellipharmaceutics Announces Cease Trade Order
Via ACCESSWIRE
News headline image
Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form
Via ACCESSWIRE
News headline image
Intellipharmaceutics International Inc. Announces Stock Option Grant
Via ACCESSWIRE
News headline image
Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange
Via ACCESSWIRE
News headline image
Intellipharmaceutics Announces Third Quarter 2023 Results
Via ACCESSWIRE
News headline image
Intellipharmaceutics Reports Director Election Results
Via ACCESSWIRE
News headline image
Intellipharmaceutics Announces Second Quarter 2023 Results
Via ACCESSWIRE
News headline image
Intellipharmaceutics Announces Third Quarter 2022 Results
Via ACCESSWIRE
News headline image
Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenlafaxine Extended-Release Tablets
Via ACCESSWIRE
News headline image
Intellipharmaceutics Announces Second Quarter 2022 Results
Via ACCESSWIRE
News headline image
Intellipharmaceutics Announces Second Quarter 2022 Results
TORONTO, ON / ACCESSWIRE / July 21, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the... 
From Intellipharmaceutics International Inc.
Via AccessWire
News headline image
Intellipharmaceutics Announces Delay in Filing Second Quarter Results Due July 15, 2022, The Financial Statements Will be Filed By July 21, 2022
TORONTO, ON / ACCESSWIRE / July 15, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the... 
From Intellipharmaceutics International Inc.
Via AccessWire
News headline image
Intellipharmaceutics Reports Director Election Results
TORONTO, ON / ACCESSWIRE / May 27, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the... 
From Intellipharmaceutics International Inc.
Via AccessWire
News headline image
Intellipharmaceutics Announces First Quarter 2022 Results
TORONTO, ON / ACCESSWIRE / April 14, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the... 
From Intellipharmaceutics International Inc.
Via AccessWire
News headline image
Intellipharmaceutics Announces Fiscal Year 2021 Results
TORONTO, ON / ACCESSWIRE / February 28, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the... 
From Intellipharmaceutics International Inc.
Via AccessWire
News headline image
Intellipharmaceutics Reports Director Election Results
TORONTO, ON / ACCESSWIRE / February 4, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in... 
From Intellipharmaceutics International Inc.
Via AccessWire
News headline image
Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene Keirstead
TORONTO, ON / ACCESSWIRE / January 13, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in... 
From Intellipharmaceutics International Inc.
Via AccessWire
News headline image
Intellipharmaceutics Comments on Recent Trading Activity
TORONTO, ON / ACCESSWIRE / December 22, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the... 
From Intellipharmaceutics International Inc.
Via AccessWire
News headline image
Intellipharmaceutics Announces Third Quarter 2021 Results
TORONTO, ON / ACCESSWIRE / October 15, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in... 
From Intellipharmaceutics International Inc.
Via AccessWire
Topics Bankruptcy Intellectual Property
News headline image
Intellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement
TORONTO, ON / ACCESSWIRE / April 22, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the... 
From Intellipharmaceutics International Inc.
Via AccessWire
News headline image
Intellipharmaceutics Announces First Quarter 2021 Results
TORONTO, ON / ACCESSWIRE / April 14, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the... 
From Intellipharmaceutics International Inc.
Via AccessWire
Topics Bankruptcy Intellectual Property